Categories: International

Glenmark Pharma opens new facility in Switzerland

New Delhi, June 10, 2014 – Glenmark Pharmaceuticals, on Wednesday, said its wholly-owned subsidiary, Glenmark Pharmaceuticals S.A., opened its new cGMP (current good manufacturing practice)-compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland.

An antibody or immunoglobulin is a protein produced by human plasma cells, and is used by the immune system to identify and neutralise foreign bodies such as virus and bacteria. The facility has been designed for use of single use bioreactor systems. It also houses a suite for manufacturing cell banks. It supplements Glenmark’s existing in-house discovery and development capabilities, and will supply material for clinical development, the company said in a statement.

Glenmark’s Swiss research centre is an integrated antibody discovery and development unit with infrastructure for conducting antibody discovery, cell line development, in vitro testing and characterization of antibodies, process development and analytical research.

Since being set up a decade ago, the centre is focused on developing novel biologic entities for treatment of pain, inflammatory, oncologic and respiratory conditions. It has filed several patents on novel biologic entities. GBR 550, its most advanced candidate, has been licensed to Sanofi and is now in Phase 2 development. GBR 900, a molecule for the treatment of chronic pain is in Phase 1 and GBR 830 an anti OX-40 antagonist, is to enter the clinic later this year.

Glenmark at present has 69 employees at the research centre and they have invented a technology platform to make bispecific antibodies — BEAT.

“We have been doing cutting edge work in the area of novel monoclonal antibodies and have several monoclonal antibody candidates and bispecific antibodies in the pipeline,’’ Michael Buschle, President, Biologics, Glenmark Pharmaceuticals, said in a statement, adding, “The manufacturing facility would help us bring these antibodies to the clinic faster and position Glenmark as a leading innovative pharmaceutical company.’’ Press Trust of India

The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

8 hours ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

1 day ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

4 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

5 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

6 days ago